Hematologic Malignancies Therapeutics Market [By Type (Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia), Lymphoma, Multiple Myeloma, and Others); By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others); and By Regions (North America - U.S., Canada; Europe - Germany, UK, France, Italy; Asia-Pacific - China, India, Japan, Australia; Latin America - Brazil, Mexico; Middle East & Africa)]: Market size & Forecast, 2018 – 2025


The Global Hematologic Malignancies Therapeutics Market Size is anticipated to reach over USD 87.0 Billion by 2025 according to a new research published by The marker research report. 

 

Hematological malignancy is a type of cancer that affect the bone marrow, blood, and lymph nodes. They include several forms of myeloma, leukemia, and lymphoma. According to an industry report in 2011, Hematological malignancies constituted 9% of all newly diagnosed malignancies in the U.S. specifying that lymphomas are more prevalent than myeloma or leukemias. Excluding Hodgkin’s lymphoma as well as acute lymphocytic leukemia, these types of malignancy are usually related to growing age. Hence, considering the aging worldwide population, malignancy type is more probable to become more prevalent.

 

The global Hematologic Malignancies Therapeutics Market growth is majorly driven by the increasing focus on development for novel treatments and growing occurrence of blood cancer. Currently, blood malignancies are the second most leading cause of cancer deaths and the 5th most common cancer. The three most common types of blood cancers are multiple myeloma leukemia, and lymphoma. Each year, approximately 400,000 people are diagnosed with lymphoma and more than 300,000 people are diagnosed with leukemia globally. In addition, inventions of novel drugs for blood cancer and its regulatory approvals are anticipated to bolster the market growth. For instance, in 2015, Pfizer announced that its antibody-drug conjugate- inotuzumab has received USFDA approval for acute lymphoblastic leukemia.  

 

The Global Hematologic Malignancies Therapeutics Market is segmented on the basis of type, therapy, and geography. Based on type, the market is segmented into leukemia, lymphoma, multiple myeloma, and others. The leukemia is further segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. On the basis of type, leukemia was estimated to dominate the market. The major market share is due to availability of products such as Imbruvica, Rituxan, and Glivec, which are estimated to be the highest revenue generating drugs. On the basis of therapy, the global Hematologic Malignancies Therapeutics Market is segmented into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others. Amongst all the therapies, chemotherapy is the most commonly used treatment with a particular drug or combination of drugs used.

 

On the basis of region, the global Hematologic Malignancies Therapeutics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America was estimated to dominate the global market. The dominance is majorly attributed to the high presence of key market players, availability of branded drugs, established healthcare organization, and increasing government support in the region. However, Asia Pacific is expected to dominate the global market during the forecast period. Increasing awareness about early diagnosis, availability of effective treatment in emerging countries, such as India and China, growing healthcare expenditure, and high unmet clinical needs of patients, are some of the factors anticipated to significantly boost the market in the Asia Pacific.

 

Some major key players in global Hematologic Malignancies Therapeutics Market includes Pfizer, Inc., F. Hoffmann-LA Roche ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson Services, Inc., and Takeda Pharmaceutical Company limited among others. The object of the key market players is to deliver better chronic care administration while keeping the cost low. In addition, the companies are concentrating on producing easy-to-use monitoring devices that can aid patients to accomplish conditions including diabetes or heart diseases better by avoiding costly medical processes.
Table of Contents
1.	Overview and Scope
1.1.	Research goal & scope
1.2.	Research assumptions
1.3.	Research Methodology
1.3.1.	Primary data sources
1.3.2.	Secondary data sources
1.4.	Key take-aways
1.5.	Stakeholders
2.	Executive Summary
2.1.	Market Definition
2.2.	Market Segmentation
3.	Hematologic Malignancies Therapeutics Market Insights
3.1.	Hematologic Malignancies Therapeutics– Industry snapshot
3.2.	Hematologic Malignancies Therapeutics- Ecosystem analysis
3.3.	Hematologic Malignancies Therapeutics Market dynamics
3.3.1.	Hematologic Malignancies Therapeutics– Market Forces
3.3.1.1.	Hematologic Malignancies Therapeutics Market driver analysis
3.3.1.2.	Hematologic Malignancies Therapeutics Market restraint/challenges analysis
3.3.1.3.	Hematologic Malignancies Therapeutics Market opportunity analysis
3.4.	Industry analysis - Porter's five force
3.4.1.	Bargaining power of supplier
3.4.2.	Bargaining power of buyer
3.4.3.	Threat of substitute
3.4.4.	Threat of new entrant
3.4.5.	Degree of competition
3.5.	Hematologic Malignancies Therapeutics Market PEST analysis, 2017
3.6.	Hematologic Malignancies Therapeutics Industry trends
3.7.	Competitive Ranking Analysis
4.	Hematologic Malignancies Therapeutics Market Size and Forecast by Type
4.1.	Key findings
4.2.	Leukemia
4.2.1.	Global market estimates and forecasts, 2017 – 2025
4.2.1.1.	Acute Lymphocytic Leukemia
4.2.1.2.	Chronic Lymphocytic Leukemia
4.2.1.3.	Acute Myeloid Leukemia
4.2.1.4.	Chronic Myeloid Leukemia
4.2.2.	Lymphoma
4.2.2.1.	Global market estimates and forecasts, 2017 – 2025
4.2.3.	Multiple Myeloma
4.2.3.1.	Global market estimates and forecasts, 2017 – 2025
4.2.4.	Others
4.2.4.1.	Global market estimates and forecasts, 2017 – 2025
5.	Hematologic Malignancies Therapeutics Market Size and Forecast by Therapy
5.1.	Key findings
5.2.	Chemotherapy
5.2.1.	Global market estimates and forecasts, 2017 – 2025
5.3.	Radiotherapy
5.3.1.	Global market estimates and forecasts, 2017 – 2025
5.4.	Immunotherapy
5.4.1.	Global market estimates and forecasts, 2017 – 2025
5.5.	Stem Cell Transplantation
5.5.1.	Global market estimates and forecasts, 2017 – 2025
5.6.	Others
5.6.1.	Global market estimates and forecasts, 2017 – 2025
6.	Hematologic Malignancies Therapeutics Market Size and Forecast by Regions
6.1.	Key findings
6.2.	North America
6.2.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.2.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.2.3.	U.S.
6.2.3.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.2.3.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.2.4.	Canada
6.2.5.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.2.6.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.	Europe
6.3.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.3.	Germany
6.3.3.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.3.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.4.	UK
6.3.4.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.4.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.5.	France
6.3.5.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.5.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.3.6.	Italy
6.3.6.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.3.6.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4.	Asia Pacific
6.4.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4.3.	China
6.4.3.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.3.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4.4.	India
6.4.4.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.4.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.4.5.	Japan
6.4.5.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.4.5.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.5.	Latin America
6.5.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.5.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.5.3.	Brazil
6.5.3.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.5.3.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.5.4.	Mexico
6.5.4.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.5.4.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
6.6.	Middle East & Africa
6.6.1.	Hematologic Malignancies Therapeutics Market by Type, 2017 - 2026
6.6.2.	Hematologic Malignancies Therapeutics Market by Therapy, 2017 - 2026
7.	Company Profiles
7.1.	Pfizer, Inc.
7.1.1.	Overview
7.1.2.	Financials
7.1.3.	Product Benchmarking
7.1.4.	Recent Developments
7.2.	Hoffmann-LA Roche ltd
7.2.1.	Overview
7.2.2.	Financials
7.2.3.	Product Benchmarking
7.2.4.	Recent Developments
7.3.	Sanofi-Aventis
7.3.1.	Overview
7.3.2.	Financials
7.3.3.	Product Benchmarking
7.3.4.	Recent Developments
7.4.	Bristol-Myers Squibb Company
7.4.1.	Overview
7.4.2.	Financials
7.4.3.	Product Benchmarking
7.4.4.	Recent Developments
7.5.	AbbVie, Inc.
7.5.1.	Overview
7.5.2.	Financials
7.5.3.	Product Benchmarking
7.5.4.	Recent Developments
7.6.	Novartis AG
7.6.1.	Overview
7.6.2.	Financials
7.6.3.	Product Benchmarking
7.6.4.	Recent Developments
7.7.	GlaxoSmithKline PLC
7.7.1.	Overview
7.7.2.	Financials
7.7.3.	Product Benchmarking
7.7.4.	Recent Developments
7.8.	Celgene Corporation
7.8.1.	Overview
7.8.2.	Financials
7.8.3.	Product Benchmarking
7.8.4.	Recent Developments
7.9.	Johnson & Johnson Services, Inc.
7.9.1.	Overview
7.9.2.	Financials
7.9.3.	Product Benchmarking
7.9.4.	Recent Developments
7.10.	Takeda Pharmaceutical Company limited
7.10.1.	Overview
7.10.2.	Financials
7.10.3.	Product Benchmarking
7.10.4.	Recent Developments


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

New Pharmaceuticals and Healthcare Reports

Internal Neuromodulation Market Forecast 2025 | Global Report

Rising number of patients suffering from neurological disorders such as Parkinson’s, essential tremor, and primary dystonia is fueling the demand for internal neuromodulation procedures. Chronic back and leg pain associated with PVD (peripheral...

Gastrointestinal Cancer Treatment Market Size 2020-2025 | Growth Forecasts

As per credible projections, gastrointestinal cancer treatment industry is expected to register strong CAGR over 2019-2025. Rising adoption of unhealthy eating habits and increasing consumption of tobacco and alcohol have increased the pervasiveness ...

Topotecan Hydrochloride Market Trends and Research Insights by 2025

As per credible estimates, global topotecan hydrochloride market is poised to acquire commendable gains by the year 2025. Rising adoption of unhealthy and sedentary lifestyle has increased the pervasiveness of small cell lung cancer, ovarian cancer, ...

Flu Vaccine Market Share 2020-2025 | Global Industry Report

As per trusted estimates, global flu vaccine market will record substantial growth during 2020-2025. Increasing government initiatives to ensure the safety of the populace, minimal side-effects associated with influenza vaccines, improving efficacy o...

Healthcare Linen Market Size - Industry Trends Report 2025

According to reliable projections, global healthcare linen market is projected to record considerable growth during 2020-2025. Rising prevalence of various diseases including cardiovascular diseases, cancer, and arthritis along with increasing cases ...

Other Reports by Polaris Market Research

Service Robotics Market Share, Size, Trends, & Industry Analysis Report, By Type (Professional Service Robotics, Personal Service Robotics); By Component (Hardware, Software, Services); By Environment; By End-User; By Region: Segment Forecast, 2018 -2026

The global service robotics market size is anticipated to reach USD 54.4 billion by 2026 growing at a CAGR of 17.3% from 2018 to 2026 according to a new report published by The marker research report. The report ‘Service Robotics Market Share, Siz...

Silicone Elastomer Market Share, Size, Trends & Industry Analysis Report By Product Type (Liquid Silicone Rubber, High Temperature Vulcanized/High Consistency Rubber, Room Temperature Vulcanized), By Process, By End-Use, By Regions]: Segment Forecast, 2018 - 2026

The global silicone elastomers market size is anticipated to reach USD 9.34 billion by 2026 growing at a CAGR of 5.1% from 2018 to 2026 according to a new report published by The marker research report. The report ‘Silicone Elastomer Market Share,...

Glycols Market Share, Size, Trends, & Industry Analysis Report, By Product (Propylene Glycol, Ethylene Glycol (Mono-ethylene Glycol, Di-ethylene Glycol, Tri-ethylene Glycol), By End-Use (Textiles, Automotive, HVAC, Medical, Airline, Others), By Regions: Segment Forecast, 2018 - 2026

The global glycols market size is anticipated to reach USD 49.36 billion by 2026 growing at a CAGR of 5.1% from 2018 to 2026 according to a new report published by The marker research report. The report ‘Glycols Market Share, Size, Trends, & Indus...

Solar Panels Market Size, Share, Trends, & Industry Analysis Report By Type (Monocrystalline Solar Panels, Polycrystalline Solar Panels, Thin-Film Solar Panels); By End-User (Residential, Commercial, Utility, Others), By Regions: Segment Forecast, 2018 - 2026

The global solar panels market size is anticipated to reach USD 90.23 billion by 2026 growing at a CAGR of 12.4% from 2018 to 2026 according to a new report published by The marker research report. The report ‘Solar Panels Market Size, Share, Tren...

Fall Protection Equipment Market Share, Size, Trends, Industry Analysis Report By Product (Hard Goods, Soft Goods, Rescue Kits, Full Body Harness and Body Belts); By Application (Oil & Gas, Construction, Transportation, Mining, Telecom, Energy & Utilities, General Industry); By Regions, Segment Forecast, 2019 - 2026

The global fall protection equipment market size is expected to reach USD 2.9 billion by 2026 according to a new study by The marker research report. The report “Fall Protection Equipment Market Share, Size, Trends, Industry Analysis Report By Prod...

Publisher: Polaris Market Research
Chat with us